PMV Pharmaceuticals, Inc.

NasdaqGS:PMVP Rapporto sulle azioni

Cap. di mercato: US$82.4m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

PMV Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

PMV Pharmaceuticals' Il CEO è David Mack, nominato in Jul2013, e ha un mandato di 11.08 anni. la retribuzione annua totale è $ 2.21M, composta da 26.5% di stipendio e 73.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.26% delle azioni della società, per un valore di $ 1.04M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.5 anni e 3.5 anni.

Informazioni chiave

David Mack

Amministratore delegato

US$2.2m

Compenso totale

Percentuale dello stipendio del CEO26.5%
Mandato del CEO11.1yrs
Proprietà del CEO1.3%
Durata media del management3.5yrs
Durata media del Consiglio di amministrazione3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

Aug 04
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Apr 20
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Dec 22
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Sep 08
We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

May 10
Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Jan 11
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Sep 22
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

Aug 09

PMV Pharma joins Merck to study lead candidate with Keytruda

Jul 18

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Jun 09
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Feb 23
Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Nov 05
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Jul 23
Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

Apr 09
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

Dec 25
Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

PMV Pharmaceuticals reports Q3 results

Nov 13

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di David Mack rispetto agli utili di PMV Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$49m

Mar 31 2024n/an/a

-US$65m

Dec 31 2023US$2mUS$586k

-US$69m

Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$74m

Dec 31 2022US$4mUS$564k

-US$73m

Sep 30 2022n/an/a

-US$72m

Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$65m

Dec 31 2021US$4mUS$545k

-US$58m

Sep 30 2021n/an/a

-US$50m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020US$1mUS$495k

-US$34m

Sep 30 2020n/an/a

-US$31m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$27m

Dec 31 2019US$628kUS$461k

-US$25m

Compensazione vs Mercato: La retribuzione totale di David ($USD 2.21M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di David è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

David Mack (62 yo)

11.1yrs

Mandato

US$2,209,795

Compensazione

Dr. David H. Mack, Ph D., Co-founded PMV Pharmaceuticals, Inc. in 2013 and also serves as its President and Chief Executive Officer since July 2013. Dr. Mack joined the PMV Pharmaceuticals, Inc. in 2013.D...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
David Mack
Co-Founder11.1yrsUS$2.21m1.26%
$ 1.0m
Arnold Levine
Co-Founder11.6yrsUS$220.27k0.80%
$ 655.7k
Deepika Jalota
Chief Development Officer5.2yrsUS$1.10m0.058%
$ 47.9k
Michael Carulli
Chief Financial Officerless than a yearNessun datoNessun dato
Robert Ticktin
General Counsel4yrsNessun datoNessun dato
Tim Smith
Senior VP and Head of Corporate Development & Investor Relations2.9yrsNessun datoNessun dato
Crystal Zuckerman
Vice President of Human Resources1.6yrsNessun datoNessun dato
Binh Vu
Senior Vice President of Drug Discovery & CMCno dataNessun datoNessun dato
Marc Fellous
Senior VP and Head of Clinical Development & Medical Affairs1.3yrsNessun datoNessun dato
Laura De Leon
VP & Head of Clinical Operationsno dataNessun datoNessun dato

3.5yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di PMVP è considerato esperto (durata media dell'incarico 3.5 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
David Mack
Co-Founder11.2yrsUS$2.21m1.26%
$ 1.0m
Arnold Levine
Co-Founder11.2yrsUS$220.27k0.80%
$ 655.7k
Charles Sawyers
Member of Clinical Advisory Boardno dataNessun datoNessun dato
Carol Gallagher
Independent Director1.8yrsUS$124.27kNessun dato
Richard Heyman
Independent Chairman of the Board of Directors & Member of Scientific Advisory Board4.2yrsUS$176.77k0%
$ 0
Scott Lowe
Chairman of Scientific Advisory Boardless than a yearNessun datoNessun dato
Charles Baum
Independent Director & Chair of Clinical Advisory Board3.3yrsUS$133.27k0%
$ 0
Laurie Stelzer
Independent Director4yrsUS$140.27k0%
$ 0
Kirsten Flowers
Independent Director2.6yrsUS$127.77k0%
$ 0
Guillermina Lozano
Member of Scientific Advisory Board3.5yrsNessun datoNessun dato

3.5yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PMVP sono considerati esperti (durata media dell'incarico 3.5 anni).